OFFICE OF FISCAL ANALYSIS
Legislative Office Building, Room 5200
Hartford, CT 06106 (860) 240-0200
http://www.cga.ct.gov/ofa
sSB-262
AN ACT REQUIRING MANUFACTURERS OF BRAND NAME
PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS
TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS.
AMENDMENT
LCO No.: 9650
File Copy No.: 12
House Calendar No.: 554
Senate Calendar No.: 48
Primary Analyst: ME 6/1/21
Contributing Analyst(s): (NF)
OFA Fiscal Note
No Fiscal Impact
The amendment strikes the underlying bill and its associated fiscal
impact resulting in the following impact. The amendment requires the
Department of Consumer Protection to study a federal Act and make
recommendations resulting in no fiscal impact.
The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely
for the purposes of information, summarization and explanation and does not represent the intent of the General
Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of
informational sources, including the analyst’s professional knowledge. Whenever applicable, agency data is
consulted as part of the analysis, however final products do not necessarily reflect an assessment from any
specific department.